Ex vivo validation of cannabinoid combinations for skin immunomodulation and wound healing

Overview

This research program investigates the immunomodulatory potential of cannabinoid compounds, including Cannabigerol (CBG), Dronabinol (THC), and Palmitoylethanolamide (PEA), individually and in combination, for managing skin inflammation. The work targets two key inflammatory cytokines, IL-6 and IL-8, which play central roles in chronic skin conditions and wound repair processes. Preliminary in vitro results using the HaCaT keratinocyte cell line demonstrated that certain cannabinoid combinations significantly reduce IL-6 and IL-8 expression at both gene and protein levels. The next phase extends this research into ex vivo skin tissue models to validate therapeutic potential and elucidate underlying molecular mechanisms.

Technical specifications

Key research findings from in vitro validation:

• Combinations of CBG, THC, and PEA modulate IL-6 and IL-8 gene and protein expression in HaCaT keratinocytes after 72 hours of stimulation
• THC+PEA combination showed the most significant reduction in IL-6 gene expression (0.24±0.07, p<0.001)
• CBG+PEA and THC+PEA combinations reduced IL-6 protein levels by approximately 50% compared to controls
• CBG+PEA combination uniquely showed IL-8 protein downregulation (52.1 pg/mL)

Planned ex vivo validation approach:

• In silico prediction of cannabinoid effects on cytokine signaling pathways
• Ex vivo skin tissue culture with selected cannabinoid combinations
• Time-course cytokine analysis at 0, 12, 24, 48, and 72 hours using flow cytometry
• Tissue viability assessment via Lactate Dehydrogenase assay at 72 hours
• Immunohistochemistry evaluation of IL-17, IL-22, IL-8, and IL-6
• Three experimental replicates per treatment with statistical significance set at p<0.05

Technology readiness level

The research is currently at an early-to-mid stage of preclinical development. In vitro proof-of-concept has been established using the HaCaT keratinocyte model, demonstrating reproducible modulation of inflammatory cytokines. The program is advancing toward ex vivo validation using intact skin tissue, which represents a critical step before potential in vivo studies or clinical translation. The combination of molecular, protein-level, and tissue-based validation approaches provides a robust framework for characterizing the therapeutic potential of cannabinoid-based interventions for inflammatory skin disorders and wound healing applications.